Absci Financial Ratios
NASDAQ: ABSIHealth CareBiotechnology: Commercial Physical & Biological ResarchUSD
10.16+1.22 (+13.65%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Absci ratio analysis
Absci earned a net margin of -4113.7% in FY 2025, down from -2274.1% a year earlier. Return on equity reached -60.8%, meaning Absci generated -0.61 dollars of profit for every dollar of shareholders' equity. Debt-to-equity stood at 0.00 versus 0.01 the year before, and the current ratio was 6.57.
Valuation ratios use the closing share price on each fiscal year-end date and diluted shares from the income statement; profitability and leverage ratios use reported annual figures. Current valuation multiples are on the statistics page.
Summary generated from market data by MetaCap's automated system. Methodology
Absci financial ratios (annual)
| Ratio | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Price / sales | 176.34 | 79.26 | 67.60 | 33.20 | 85.20 | — |
| Price / book | 2.61 | 2.01 | 2.19 | 0.70 | 1.11 | — |
| Operating margin | -4,297.0% | -2,401.6% | -2,020.2% | -1,857.5% | -1,573.4% | -278.3% |
| Net margin | -4,113.7% | -2,274.1% | -1,933.6% | -1,825.4% | -2,111.3% | -300.3% |
| Free cash flow margin | -3,358.3% | -1,605.8% | -1,145.4% | -1,696.8% | -2,062.8% | -275.1% |
| Return on equity (ROE) | -60.8% | -57.6% | -62.8% | -38.2% | -27.6% | — |
| Return on assets (ROA) | -53.3% | -48.3% | -50.9% | -32.7% | -23.7% | -16.2% |
| Debt / equity | 0.00 | 0.01 | 0.03 | 0.03 | 0.00 | — |
| Current ratio | 6.57 | 4.67 | 4.08 | 6.17 | 8.07 | 7.25 |
| Revenue growth | -38.2% | -20.7% | -0.5% | 20.2% | 0.0% | — |